Myelodysplastic syndromes: Recent advances

Haematologica

Volumn 86, Issue 11, 2001, Pages 1124-1157

  Alessandrino, E P ^a   Amadori, S ^a   Cazzola, M ^a   Locatelli, F ^a   Mecucci, C ^a   Morra, E ^a   Saglio, G ^a   Visani, G ^a   Tura, S ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AMIFOSTINE; BENZENE DERIVATIVE; CALICHEAMICIN; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; EPIPODOPHYLLOTOXIN; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GENE PRODUCT; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IDARUBICIN; INTERLEUKIN 3; MELPHALAN; ORGANIC SOLVENT; PROTEIN NF1; RAS PROTEIN; RECOMBINANT ERYTHROPOIETIN; THYMOCYTE ANTIBODY; TIOGUANINE; TOPOTECAN; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG;

AGE DISTRIBUTION; BLOOD TOXICITY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DISEASE CLASSIFICATION; DNA REPAIR; DOSE RESPONSE; ENVIRONMENTAL FACTOR; GENE ACTIVATION; GENE DELETION; GENE MUTATION; GENETIC PREDISPOSITION; HUMAN; IONIZING RADIATION; MICROSATELLITE INSTABILITY; MYELODYSPLASTIC SYNDROME; PREVALENCE; PROGNOSIS; REVIEW; RISK FACTOR; SEX RATIO; STEM CELL; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

AGE FACTORS; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; CYTOGENETIC ANALYSIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MYELODYSPLASTIC SYNDROMES;

EID: 0035164689     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (260)

1. Pathogenesis, etiology and epidemiology of myelodysplastic syndromes
2. A hypothesis for the pathogenesis of myelodysplastic syndromes: Implications for new therapies
3. Achievements in understanding and treatment of myelodysplastic syndromes
4. X-inactivation analysis in the 1990s: Promise and potential problems
5. Clonal development of myeloproliferative disorders: Clues to hematopoietic differentiation and multistep pathogenesis of cancer
6. Exposure to occupational and environmental factors in myelodysplastic syndromes. Preliminary results of a case-control study
7. Exposure to myelotoxic agents and myelodysplasia: Case-control study and correlation with clinicobiological findings
8. Cytogenetic abnormalities in the myelodysplastic syndromes and occupational or environmental exposure
9. Overview of benzene-induced aplastic anaemia
10. The toxicity of benzene and its metabolism and molecular pathology in human risk assessment
11. Metabolic basis of benzene toxicity
12. Benzene metabolites induce the loss and long arm deletion of chromosomes 5 and 7 in human lymphocytes
13. Alternative to conventional or myeloablative chemotherapy in myelodysplastic syndrome
14. Antithymocyte globulin for patients with myelodysplastic syndrome
15. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow
16. Depletion of lymphocytes increases the in vitro hemopoiesis in long-term bone marrow cultures (LTBMC) from patients with myelodysplastic syndrome (MDS): Implications for the immunosuppressive therapy
17. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells
18. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes
19. Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: Relation to disease progression
20. Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression
21. Tumor-suppressor P53: Implication for tumor development and prognosis
22. Myelodysplastic and myeloproliferative disorders of childhood: A study of 167 patients
23. Paroxysmal nocturnal haemoglobinuria: Long-term follow-up and prognostic factors
24. Malignant tumors occurring after treatment of aplastic anemia
25. γ-interferon gene expression in the bone marrow of patients with aplastic anemia
26. Overexpression of tumor necrosis factor (TNF)-α and interferon (IFN)-γ by bone marrow cells from patients with myelodysplastic syndromes
27. Radiogenic leukemia revisited
28. α-particle-induced chromosomal instability in human bone marrow ̄ells
29. Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype
30. Risk of acute myelogenous leukemia and myelodysplasia following cancer treatment
31. Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy
32. Smoking and myelodysplastic syndromes
33. Hair dye use and occupational exposure to organic solvents as risk factors for myelodysplastic syndrome
34. Use of hair dyes, hematopoietic neoplasms, and lymphomas: A literature review. I. Leukemias and myelodysplastic syndromes
35. Incidence rates of myelodysplastic syndromes (MDS) in a Northern-Spanish area
36. Update of epidemiological characteristics of myelodysplastic syndrome in a well-defined French population between 1980 and 1995
37. Increasing incidence of myelodysplastic syndromes: Real or fictitious?
38. Proposals for the classification of the myelodysplastic syndromes
39. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997
40. International scoring system for evaluating prognosis in myelodysplastic syndromes
41. Therapy-related myeloid leukemia
42. Establishing the incidence of MDS
43. Incidence of myelodysplastic syndromes in a Swedish population
44. Establishing the incidence of myelodysplastic syndrome
45. Myelodysplastic syndromes: A scoring system with prognostic significance
46. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: A multivariate analysis of prognostic factors in 370 patients
47. Primary myelodysplastic syndromes: Analysis of prognostic factors in 235 patients and proposals for an improved scoring system
48. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: A report on 408 cases
49. Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: A multicentric study in Japan
50. Myelodysplastic syndromes
51. The myelodysplastic syndromes: Different evolution patterns based on sequential morphological and cytogenetic investigations
52. Bone marrow biopsy in myelodysplastic syndromes: Morphological characteristics and contribution to the study of prognostic factors
53. Prognostic factors for myelodysplastic syndromes: A simplified 3-D scoring system
54. Life expectancy in primary myelodysplastic syndromes: A prognostic score based upon histopathology from bone marrow biopsies of 569 patients
55. Myelodysplastic syndromes. A multiparametric study of prognostic factors in 336 patients
56. Prognostic factors in the myelodysplastic syndromes: Importance of initial data on peripheral blood counts, bone marrow cytology, trephine biopsy and chromosomal analysis
57. Cytogenetics of myelodysplastic syndromes
58. The 5q-anomaly
59. Bone marrow karyotype and prognosis in primary myelodysplastic syndromes
60. Chemotherapy of secondary leukemias
61. Myelodysplastic syndromes
62. FISH (fluorescent in situ hybridization): The second youth of cytogenetics
63. Deletion of chromosome 20q in myelodysplasia can occur in a multipotent precursor of both myeloid cells and B cells
64. Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: Evidence for involvement at the hematopoietic stem cell level
65. Combined immunophenotyping and FISH identifies the involvement of B-cells in 5q-syndrome
66. Cytogenetic characteristics of therapy-related acute nonlymphocytic leukaemia, preleukaemia and acute myeloproliferative syndrome: Correlation with clinical data for 61 consecutive cases
67. Interphase cytogenetics by fluorescent in situ hybridization (FISH) for characterization of monosomy-7-associated myeloid disorders
68. Monosomy 7 myeloproliferative disease in children with neurofibromatosis, type 1: Epidemiology and molecular analysis
69. Myelodysplasia syndrome and acute myeloid leukemia in patients with congenital neutropenia receiving GCSF therapy
70. Childhood monosomy 7: Epidemiology, biology, and mechanistic implications
71. Defective chemotaxis in monosomy 7
72. Molecular definition of a narrow interval at 7q22.1 associated with myelodysplasia
73. Molecular cytogenetic delineation of deletions and translocations involving chromosome band 7q22 in myeloid leukemias
74. Molecular anatomy of chromosome 7q deletions in myeloid neoplasms: Evidence for multiple critical loci
75. Molecular cytogenetic characterization of a critical region in bands 7q35-q36 commonly deleted in malignant myeloid disorders
76. Distinct haematological disorder with deletion of long arm of no. 5 chromosome
77. Cytokine therapy for myelodysplastic syndrome
78. 5q-, twenty-five years later: A synopsis
79. Dic(5;17): A recurring abnormality in malignant myeloid disorders associated with mutations of TP53
80. Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases
81. The 5q- syndrome
82. Physical mapping of the minimal region of loss in 5q- chromosome
83. Delineation of a minimal interval and identification of 9 candidates for a tumor suppressor gene in malignant myeloid disorders on 5q31
84. Distinct genetic involvement of the TP53 gene in therapy-related leukemia and myelodysplasia with chromosomal losses of Nos 5 and/or 7 and its possible relationship to replication error phenotype
85. Deletions of chromosome 5q13.3 and 17p loci cooperate in myeloid neoplasms
86. 17p deletion in acute myeloid leukemia and myelodysplastic syndrome. Analysis of breakpoints and deleted segments by fluorescence in situ
87. Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of p53 mutations
88. The EVI1 gene in myeloid leukemia
89. Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations
90. A cDNA probe detects all rearrangements of the MLL gene in leukemias with common and rare 11q23 translocations
91. Correlation of MLL breakpoints in 11q23 rearrangements with topoisomerase II consensus binding sites, Alu sequences and scaffold attachment regions
92. Chromatin remodeling and leukemia: New therapeutic paradigms
93. Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia
94. Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells
95. Haplo-insufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia
96. Trisomy 13 in acute leukemia
97. Acute myeloid leukemia with t(6;9)(p23;q34). Association with myelodysplasia, basophilia, and initial CD34 negative immunophenotype
98. TEL gene is involved in myelodysplastic syndromes with either the typical t(5;12)(q33;p13) translocation or its variant t(l0,12)(q24;pl3)
99. H4(D10S170) a gene frequently rearranged in papillary thyroid carcinoma is fused to the platelet-derived growth factor receptor β (PDGFBR) gene in atypical chronic myeloid leukemia with a t(5;10) (q33,q22)
100. The molecular basis of myelodysplastic syndromes
101. Loss of NF1 results in activation of the Ras signalling pathway and leads to aberrant growth in haematopoietic cells
102. A chromosomal profile of polycythemia vera
103. Molecular delineation of 13q deletion boundaries in 20 patients with myeloid malignancies
104. Trisomy 8 in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)
105. Translocation (Y;1)(q12;q12) in hematologic malignancies. Report on two new cases, FISH characterization, and review of the literature
106. An identical translocation between chromosome 1 and 15 in two patients with myelodysplastic syndromes
107. Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: Potential prognostic implications
108. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
109. Prognostic factors and scoring systems in myelodysplastic syndromes
110. A patient-oriented approach to treatment of myelodysplastic syndromes
111. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders
112. Clinical use of recombinant human erythropoietin outside the setting of uremia
113. Prediction of response to treatment with human recombinant erythropoietin in myelodysplastic syndromes
114. Red cell precursor mass as an independent determinant of serum erythropoietin level
115. Erythropoietin in myelodysplastic syndromes: Durable response in a young patient
116. Treatment of the anaemia of myelodysplastic syndromes using human granulocyte-CSF in combination with erythropoietin
117. A combination of granulocyte-colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromes
118. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: Evidence for in vivo synergy
119. Treatment of the anemia in MDS with G-CSF and Epo: Final report from a randomized study
120. Trilineage recovery by combination therapy with recombinant human granulocyte colony-stimulating factor and erythropoietin in patients with aplastic anemia and refractory anemia
121. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: Proposal for a predictive model
122. Recombinant human granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin may improve anemia in selected patients with myelodysplasia
123. The use of GM-CSF+/- r-HuEpo for the treatment of cytopenias associated with myelodysplastic syndromes
124. Combined treatment of myelodysplastic syndromes (MDS) with recombinant human Interleukin 3 and erythropoietin (EPO)
125. Treatment of myelodysplastic syndromes (MDS) with the combination of interleukin 3 and erythropoietin
126. Differentiation therapy in myelodysplastic syndromes
127. The potential of amifostine: From cytoprotectant to therapeutic agent
128. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome
129. Poor response rate to a continuous schedule of Amifostine therapy for "low/intermediate risk" myelodysplastic patients
130. Amifostine in the treatment of low-risk myelodysplastic syndromes
131. The aplasia-myelodysplasia enigma: A reemerging question
132. Immunosuppressive therapy for hypoplastic myelodysplastic syndrome
133. Prolonged response to cyclosporin-A in hypoplastic refractory anemia and correlation with in vitro studies
134. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome
135. Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS
136. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG)
137. Polyclonal primitive hematopoietic progenitors can be detected in mobilized peripheral blood from patients with high-risk myelodysplastic syndromes
138. In vivo mobilization of karyotypically normal peripheral blood progenitor cells in high-risk MDS, secondary or therapy-related acute myelogenous leukemia
139. Low-dose ARA-C in acute nonlymphocytic leukemia and myelodysplastic syndromes: A review of 20 years experience
140. Low-dose melphalan for treatment of high-risk myelodysplastic syndromes
141. Low-dose melphalan induces favourable responses in elderly patients with high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia
142. Successful oral chemotherapy with idarubicin in refractory anaemia with excess blasts
143. High-dose cytosine arabinoside in the treatment of preleukemic disorders: A Leukemia Intergroup Study
144. Short remission durations in therapy-related leukemia despite cytogenetic responses to high-dose cytarabine
145. Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia
146. Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia
147. DNA demethylating therapy in MDS: The experience with 5-aza-2′-deoxycytidine (decitabine)
148. Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia
149. Morphological classification, response to therapy, and survival in 263 adult patients with acute nonlymphoblastic leukemia
150. Intensive chemotherapy in childhood myelodysplastic syndrome: A comparison with results in acute myeloid leukemia
151. Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: A Cancer and Leukemia Group B study
152. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy
153. S-HAM induction chemotherapy with or without GM-CSF in patients with high-risk myelodysplastic syndromes
154. Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy
155. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia
156. Fludarabine, cytarabine, and G-CSF for the treatment of high-risk myelodysplastic syndromes
157. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia
158. Expression of the multidrug resistance P-glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes
159. Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P-glycoprotein: Results of a randomized study
160. Clinical use of hematopoietic growth factors in the myelodysplastic syndromes
161. Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS
162. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: Comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor
163. Aggressive chemotherapy in MDS: The Dusseldorf experience
164. Efficacy and safety of CMA-676 in patients with AML in first relapse
165. Feasibility of peripheral blood progenitor cell harvest and transplantation in patients with poor-risk myelodysplastic syndromes
166. Haemopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute leukaemias: A report on behalf of the Chronic Leukaemia Working Party of the European Groups for Blood and Marrow Transplantation
167. Allogeneic bone marrow transplantation for myelodysplastic syndromes: Outcomes analysis according to IPSS score
168. Hemopoietic stem cell transplantation for myelodysplastic syndrome
169. Bone marrrow transplantation from HLA identical siblings as first line treatment in patients with myelodysplastic syndromes: Early transplantation is associated with improved outcome
170. Allogeneic bone marrow transplantation for chronic myelomonocytic leukemia in chidhood: A report from the European Working Group on Myelodysplastic Syndrome in Childhood
171. Allogeneic marrow transplantation in the treatment of preleukemia
172. Bone marrow transplantation for patients with myelodysplasia. Pretreatment variables and outcome
173. Partially matched bone marrow transplantation in patients with myelodysplastic syndromes
174. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: A survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG)
175. Bone marrow transplantation for myelodysplastic and myeloproliferative syndromes
176. Bone marrow transplantation for myelodysplasia and secondary acute nonlymphoblastic leukemia
177. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age
178. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program
179. Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute leukemia: An EBMT survey
180. Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia
181. Allogeneic marrow transplantation for refractory anemia: A comparison of two preparative regimens and analysis of prognostic factors
182. Unrelated donor bone marrow transplantation for refractory anemia
183. Myelodysplastic syndrome or leukemia developing after MDS treated by allogeneic bone marrow transplantation: Outcome of 90 adult patients
184. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: A phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors
185. Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia
186. Bone marrow transplantation for myelodysplasia: The IBMTR data 192
187. Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS
188. Stem cell transplantation for secondary acute myeloid leukemia: Evaluation of transplantation as initial therapy or following induction chemotherapy
189. Bone marrow transplantation for secondary leukemia. Report of two cases
190. Cytogenetic abnormalities in primary myelodysplastic syndromes are highly predictive of outcome after allogeneic bone marrow transplantation
191. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: A long term study of 71 patients
192. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non malignant hematologic disease
193. Bone marrow transplantation from unrelated donor in myelodysplastic syndromes
194. MUD in BMT in MDS/sAML: An EBMT survey
195. Myelodysplastic syndromes: The pediatric point of view
196. Myelodysplastic syndromes
197. Preleukemia in children
198. A population-based study of childhood myelodysplastic syndrome in British Columbia, Canada
199. Myeloid neoplasia in children treated for solid tumours
200. Leukemia following Hodgkin's disease
201. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia
202. Familial partial monosomy 7 and myelodysplasia: Different parental origin of the 7 suggests the action of a mutator gene
203. Evidence implicating heterozygous deletion of chromosome 7 in the pathogenesis of familial leukemia associated with monosomy 7
204. Familial acute myeloid leukemia with monosomy 7: Late onset and involvement of a multipotential progenitor cell
205. Linkage of a familial platelet disorder with a propensity to develop myeloid malignancies to human chromosome 21q22.1-22.2
206. Hematologic abnormalities in Fanconi anemia: An International Fanconi Anemia Registry study
207. Myelodysplastic syndromes in childhood. Report of 21 patients from Italy and West Germany
208. Experience in pediatric myelodysplastic syndromes
209. Chronic myelomonocytic leukemia in childhood: A retrospective analysis of 110 cases
210. Juvenile myelomonocytic leukemia
211. Subacute and chronic myelomonocytic leukemia in children (juvenile CML). Clinical and hematologic observations, and identification of prognostic factors
212. Juvenile chronic myelogenous leukemia
213. The value of intensive combination chemotherapy for juvenile chronic myelogenous leukemia
214. Residual juvenile chronic myelogenous leukemia cells detected in peripheral blood during clinical remission
215. Juvenile chronic myelogenous leukemia: Characterization of the disease using cell cultures
216. Cell culture studies and oncogene expression in juvenile chronic myelogenous leukemia
217. Granulocyte-macrophage colony-stimulating factor is an endogenous regulator of cell proliferation in juvenile chronic myelogenous leukemia
218. The role of monocyte-derived hemopoietic growth factors in the regulation of myeloproliferation in juvenile chronic myelogenous leukemia
219. Central role of tumour necrosis factor, GM-CSF, and interleukin 1 in the pathogenesis of juvenile chronic myelogenous leukaemia
220. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor is toxic to blasts from patients with juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia
221. Modulation of granulocyte-macrophage colony-stimulating factor gene expression by a tumor necrosis factor specific ribozyme in juvenile myelomonocytic leukemic cells
222. The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae
223. The NF1 gene in myelopoiesis and childhood myelodysplastic syndromes
224. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant disorders
225. Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1
226. Genetic analysis is consistent with the hypothesis that NF1 limits myeloid cell growth through p21ras
227. Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyltransferase inhibitors
228. Recommendations for a morphologic, immunologic, and cytogenetic (MIC) working classification of the primary and therapy-related myelodysplastic disorders. Report of the workshop held in Scottsdale, Arizona, USA, on February 23-25, 1987
229. The myelodysplastic syndromes: Current approaches to therapy
230. AML-type intensive chemotherapy prior to stem cell transplantation (SCT) does not improve survival in children and adolescents with primary myelodysplastic syndromes (MDS)
231. Intensively timed induction therapy followed by autologous or allogeneic bone marrow transplantation for children with acute myeloid leukemia or myelodysplastic syndrome: A Childrens' Cancer Group pilot study
232. Treatment of juvenile chronic myeloid leukemia with sequential subcutaneous cytarabine and oral mercaptopurine
233. A pilot study of isotretinoin in the treatment of juvenile chronic myelogenous leukemia
234. Allogeneic bone marrow transplantation for children with juvenile chronic myelogenous leukemia
235. Bone marrow transplantation for children with myelodysplastic syndromes
236. Role of allogeneic bone marrow transplantation from HLA-identical sibling or a matched unrelated donor in the treatment of children with juvenile chronic myeloid leukaemia
237. Role of busulfan and total body irradiation on growth of prepubertal children receiving bone marrow transplantation and results of treatment with recombinant human growth hormone
238. Beyond the FAB classification for myelodysplastic syndromes
239. The myelodysplastic syndromes: Predictive value of eight prognostic systems in 143 cases from a single institution
240. p53 overexpression in refractory anemia. An immunohistochemical analysis of bone marrow biopsies
241. The pathogenesis and management of essential thrombocythaemia
242. The differential diagnosis between aplastic anemia and hypocellular myelodysplasia in patients with pancytopenia
243. Treatment of myelodysplastic syndromes
244. Allogeneic bone marrow transplantation for secondary leukemia or myelodysplasia
245. Combined use of erythropoietin and G-CSF in the treatment of myelodysplastic syndromes
246. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders
247. The molecular basis of paroxysmal nocturnal hemoglobinuria
248. Heterogeneity of isolated mononuclear cells from patients with acute myeloid leukemia affects cellular accumulation and efflux of daunorubicin
249. Prolonged response to cyclosporin-A in hypoplastic refractory anemia and correlation with in vitro studies
250. Identification of a group of AML/MDS patients with a relatively favorable prognosis who have chromosome 5 and/or 7 abnormalities
251. Amifostine in the treatment of low-risk myelodysplastic syndromes
252. Incidence and characterization of secondary myelodysplastic syndromes following autologous transplantation
253. A case of atypical myelodysplastic syndrome with a novel reciprocal translocation t(1;12)(q21;p13)
254. Transformation of severe aplastic anemia into myelodysplastic syndrome with monosomy 7: Monoclonal origin detected by HUMARA gene analysis during the aplastic anemia phase
255. Dihydrofolate reductase activity in the erythroblasts of patients with 5q- syndrome
256. Sweet's syndrome and myelodysplasia: Two entities with a common pathogenetic mechanism? A case report
257. Might arsenic trioxide be useful in the treatment of advanced myelodysplastic syndromes?
258. Expression of CD34 by megakaryocytes in myelodysplastic syndromes
259. Differences in phenotype, growth factor requirements, pattern of expression of adhesion molecules and rate of apoptosis displayed by three new myeloid sister leukemic cell lines